ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IRIX IRIDEX Corporation

1.64
-0.07 (-4.09%)
20 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
IRIDEX Corporation NASDAQ:IRIX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.07 -4.09% 1.64 1.55 1.68 1.73 1.6201 1.695 29,267 21:43:21

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

13/11/2023 2:00pm

GlobeNewswire Inc.


IRIDEX (NASDAQ:IRIX)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more IRIDEX Charts.

Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY.

Third Quarter Earnings Conference CallThe Company’s management team will host a conference to discuss reported financial results and business updates beginning at 2:00 p.m. PT / 5:00 p.m. ET on November 14, 2023.

Stifel 2023 Healthcare ConferenceManagement is scheduled to present on Wednesday, November 15 at 10:20 a.m. ET.

Investors interested in listening to the conference call and presentation may do so by accessing the live and recorded webcasts on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.

About IridexIridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Investor Relations Contact:Philip TaylorGilmartin Groupinvestors@iridex.com

 

1 Year IRIDEX Chart

1 Year IRIDEX Chart

1 Month IRIDEX Chart

1 Month IRIDEX Chart

Your Recent History

Delayed Upgrade Clock